FDA has indicated Karyopharm Therapeutics‘ nuclear export inhibitor Xpovio for relapsed or refractory multiple myeloma (RRMM).
The indication covers its use in conjunction with the steroid dexamethasone. Patients receiving the drug should receive at least four previous therapies. Furthermore, the indication covers patients with myeloma that is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti‐CD38 monoclonal antibody.
Xpovio has also won conditional marketing authorization in the European Union for patients with heavily pretreated multiple myeloma.
Filed Under: Oncology